Grail (GRAL) stock plunged around 50% in after-hours trading Thursday after the biotech company’s cancer trial results disappointed investors.
February 20, 2026 - 15:58
By Pharos Investment Advisors Comments are Off
Grail (GRAL) stock plunged around 50% in after-hours trading Thursday after the biotech company’s cancer trial results disappointed investors.
Regulated by Hellenic Capital Market Commission
with Registration Number 5/700/10.12.2014

Copyright 2023©. All Rights Reserved